Glucosamine supplement linked to faster progression to dementia

Glucosamine supplement use is associated with a faster progression from mild cognitive impairment to dementia and higher mortality in Alzheimer's patients. An analysis of deidentified UF Health records from 2012 to 2024 found glucosamine use was linked to a 25% higher likelihood of MCI progressing to dementia after adjusting for age, sex, and demographics. Among those with Alzheimer’s disease or related dementias, glucosamine use correlated with a 25% increase in mortality risk.

The study investigated patients diagnosed with ADRD or mild cognitive impairment. About 8% of patients in both groups reported using the supplement. This included 1,896 people with ADRD and 2,750 people with MCI who used glucosamine. No mortality association was observed in the MCI group alone. The research used a retrospective analysis of patient health records, human brain tissue experiments, and mouse models of Alzheimer’s disease.

Biological mechanism identified in brain tissue and models

Researchers identified a biological mechanism involving the attachment of sugar structures to proteins. Glucosamine is a naturally occurring sugar-related molecule that can cross the blood-brain barrier. Once in the brain, it can enter biochemical pathways that construct and attach these sugar tags to proteins.

This metabolic pathway typically matters in cellular biology but was found to be excessively active in Alzheimer’s disease. In genetically modified mice, glucosamine increased sugar residue attachment to proteins and worsened social memory deficits. Interventions inhibiting this sugar attachment process improved memory performance in treated mice.

Analysis of human brain tissue from Alzheimer’s patients revealed significantly higher levels of this sugar attachment compared to non-affected individuals. The findings suggest abnormal metabolic processes could play a primary role in Alzheimer’s progression rather than being merely a consequence.

Experts call for caution and further study

The study does not prove causation, showing only an observational association. Senior author Ramon Sun noted that a lot of people actively take an over-the-counter supplement that could be making their disease progression worse. He stated that altered metabolism appears to be a significant contributor to Alzheimer’s disease progression.

Study co-author Matt Gentry called the electronic health record data very provocative. He emphasized that while it is an association and not proof of causality, it raises an important clinical question that now deserves much more attention. Gentry explained that proteins need sugar tags added correctly to function, and in Alzheimer's this system is overactive, contributing to the disease.

The results do not urge individuals to discontinue glucosamine use. The findings are preliminary and require validation through human clinical trials. A controlled human clinical trial is necessary to determine if glucosamine accelerates Alzheimer’s progression and identify at-risk patients. Abnormal activity in this metabolism may emerge as a target for future therapeutic interventions.

Context on Alzheimer's prevalence and supplement use

Glucosamine is a popular over-the-counter supplement commonly used for joint pain. In the United States, there are about 7 million people living with Alzheimer's and millions more with related dementias. Many of these individuals are likely using glucosamine.

Mild cognitive impairment is characterized by noticeable memory or thinking problems greater than expected with aging, without significant interference in daily life. The research team used innovative spatial technology to investigate metabolic changes influenced by glucosamine. Effects of glucosamine may differ in healthy brains versus those impacted by Alzheimer’s disease. Variations in individual health profiles and other factors could influence outcomes.

Future treatments could focus on addressing these metabolic defects alongside conventional therapies targeting plaques and tangles. The electronic health record findings raise critical questions requiring more extensive exploration. A controlled human clinical trial is necessary to determine if glucosamine accelerates Alzheimer’s progression and identify at-risk patients.